Starpharma Holdings Limited · ASX:SPL
Starpharma — Shareholder Meeting (November 2024)
43 slides from Starpharma's shareholder meeting presentation, Nov 26, 2024
Slide 1: AGM Chair Address and CEO Presentation
ASX Announcement AGM Chair Address and CEO Presentation Melbourne, Australia; 26 November 2024: Starpharma (ASX: SPL, US OTC: SPHRY), an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient, today provides a copy of the Chair’s
Slide 2: Chair's Address to Shareholders
Starpharma Holdings Limited Annual General Meeting 26 November 2024 Chair’s Address to Shareholders Good afternoon, fellow shareholders. Welcome to Starpharma’s 2024 Annual General Meeting. On behalf of the Board of Directors, I want to thank you for joining us today and for your continued support o
Slide 3: Addressing Challenges and Renewed Focus
company is completing the necessary optimisation research and preclinical activities to ensure that any assets that advance to the clinic are poised to offer a competitive advantage in the market. Cheryl will soon deliver a detailed operational update during her presentation. Addressing Challenges a
Slide 4: Delivering Meaningful Patient Outcomes with Advanced Dendrimer Technology
ASX : SPL US OTC : SPHRY Delivering Meaningful Patient Outcomes with Advanced Dendrimer Technology Annual General Meeting | 26 November 2024 CEO, Cheryl Maley Annual General Meeting 2024
Slide 5: 2
2
Slide 6: Our Mission
“To help patients with significant illnesses, such as cancer, achieve Our Mission improved health outcomes and quality of life through the application of our unique dendrimer technology.” Annual General Meeting 2024 3
Slide 7: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, Starpharma can give no assurance that these expecta
Slide 8: The Dendrimer Platform Technology
The Dendrimer Platform Technology: Clinically Validated, Benefits Recognised Annual General Meeting 2024 5
Slide 9: Starpharma – Founders and Experts in Dendrimer Drug Delivery
Starpharma – Founders and Experts in Dendrimer Drug Delivery Dendrimers are highly branched (tree-like) macromolecules with a well-defined, 3D structure Cytotoxic Dendrimer Generations Ultra-toxic Radioisotope / Chelator Immunomodulator G1 G2 G3 G4 • Concentric layers of lysine monomers • Drugs, pay
Slide 10: Starpharma's Portfolio
Starpharma’s Portfolio: Multiple Clinical-stage Assets, Partnerships and Products In Market Internal DEP® Pipeline Partnered DEP® Programs Target Pre- Product Research Phase I Phase II Phase III Strategy indication clinical License/co- Ovarian and DEP® SN38 colorectal Phase II results reported devel
Slide 11: Annual General Meeting 2024
Annual General Meeting 2024 8
Slide 12: DEP SN38 Phase I/II Trial Patients
DEP® SN38 Phase I/II Trial Patients – Advanced, Heavily Pre-treated, and Most CRC Patients had Progressed Following Prior Treatment with Irinotecan Results Presented at the 2024 ASCO Annual Meeting BASELINE CHARACTERISTICS COLORECTAL OVARIAN PANCREATIC BREAST OTHER1 TOTAL Subjects enrolled (n, %) 55
Slide 13: DEP SN38 Phase II Study Shows Favourable Data
DEP® SN38 Phase II Study Shows Favourable Efficacy and Tolerability Data in Late-Stage Patients Results Presented at the 2024 ASCO Annual Meeting Advanced Colorectal Cancer Gastrointestinal Toxicity Profile Significantly Improved with DEP® SN38 Treatment, Compared to Published Data on Irinotecan# 5
Slide 14: DEP Cabazitaxel Phase I/II Trial Patients
DEP® Cabazitaxel Phase I/II Trial Patients – Advanced, Heavily Pre-treated, and Majority had Progressed Following Prior Taxane Therapy Results Presented at the 2024 ASCO Annual Meeting HEPATO- PATIENT BASELINE CHARACTERISTICS PROSTATE OVARIAN EGC HNSCC OTHER* TOTAL BILIARY Patients enrolled (n, %) 2
Slide 15: DEP Cabazitaxel Achieves Encouraging Efficacy
DEP® Cabazitaxel Achieves Highly Encouraging Efficacy in Late- Stage Patients, Compared to Standard Therapies Results Presented at the 2024 ASCO Annual Meeting DEP® Cabazitaxel in Advanced Prostate Cancer 41.80% Jevtana^ DEP® cabazitaxel 5 4.4 20 4 13.4 14.7 N=5801 N=251 2.9 15 3 10 2 Low rates or a
Slide 16: Addressing the Biodistribution Challenges
Addressing the Biodistribution Challenges of Current Approaches with DEP® Radiotheranostics Biodistribution Challenges Starpharma’s DEP® Technology Solution: with Other Approaches: Tumour:Kidney/Organ DEP® HER2 radiodiagnostic: faster Tumour:Kidney ratio highly negative Tumour:Blood ratio >40 ratios
Slide 17: Key Learnings from Partnerships
Key Learnings from Partnerships Dendrimer • Ability to modify the pharmacokinetics of drugs to suit technology offers desired characteristics, including enhanced solubility AstraZeneca Case Study significant value and widening the therapeutic window in drug ➢ Demonstrated Starpharma’s • Applicable t
Slide 18: Benefits of Starpharma's DEP Platform Technology
Benefits of Starpharma’s DEP® Platform Technology Apply to a Wide Range of Therapeutic Areas Ability to use a wide range of targeting moieties Site-specific attachment of dendrimer on targeting moiety DEP® dendrimers are precisely manufactured and easily scalable Drug-linker strategy flexibility Key
Slide 19: The Commercial Opportunity
The Commercial Opportunity: Our Strategy For Unlocking SPL Value Annual General Meeting 2024 16
Slide 20: Starpharma's DEP Platform Technology
Starpharma’s DEP® Platform Technology: Versatile and Multifunctional for Delivery of Therapeutics and Diagnostics Multiple Opportunities to Maximise Shareholder Returns DEP® SN38 and DEP® cabazitaxel: Phase II commercial opportunities to address Clinical unmet needs in oncology Assets Radiodiagnosis
Slide 21: Strategic Review in May Confirmed Three Key Focus Areas
Strategic Review in May Confirmed Three Key Focus Areas to Optimise Shareholder Returns 01 02 03 Maximise DEP® Accelerate early Build long-term asset value asset sustainability development Increasing revenue, Prioritising DEP® SN38 and DEP® Advancing DEP® strengthening IP position, and cabazitaxel r
Slide 22: Short- and Medium-Term Priorities Announced in May 2024
Short- and Medium-Term Priorities Announced in May 2024 Significant Progress Made Across All Priorities Since May Our Immediate Short Medium Approach 0 – 9 months 9 – 18 months 18 – 24 months License DEP® asset/s Radio and ADC Development Radiotheranostic collaboration Maximise DEP® asset value Adva
Slide 23: Maximise DEP Asset Value
Phase II Clinical Assets Rapidly Maximise DEP Strategic ® Partnerships Emerging Therapies DEP Asset Value Platform OTC Future Products on Opportunities Market Annual General Meeting 2024 20
Slide 24: DEP Clinical Assets Offer a De-risked Development Program
DEP® Clinical Assets Offer a De-risked Development Program with an Established Market Opportunity Chemotherapies remain standard-of- DEP® delivery improved anticancer Demonstrated ability to overcome care and form the backbone of efficacy and tolerability in multiple anticancer treatment resistance
Slide 25: DEP SN38 & DEP Cabazitaxel
DEP® SN38 & DEP® Cabazitaxel Committed to Unlocking Global Commercial Opportunities Both assets were developed DEP® SN38 Phase II Results Indication Evaluation using the DEP® technology to improve existing oncology Clinically meaningful outcomes were achieved for patients who Advanced DEP® SN38 were
Slide 26: Significant Progress in 2024 in Partner-Readiness
We Have Made Significant Progress in 2024 in Our Partner- Readiness & Highly Focused Partner Engagement Clinical & Clinical Phase Commercial pathway and I/II results & assessment: regulatory strategic Indications advice, tech review prioritised transfer ASCO BD resources License / presentations incr
Slide 27: Accelerate Early Asset Development
Phase II Clinical Assets Rapidly Strategic Accelerate Early Emerging Partnerships Therapies DEP Asset Development Platform Novel Areas OTC of Unmet Products on Need Market Annual General Meeting 2024 24
Slide 28: Starpharma's Proprietary DEP Technology
Starpharma’s Proprietary DEP® Technology Has the Potential to Address Limitations of a Wide Range of Diagnostics and Therapies DEP® Nano molecule The Problem The Solution Despite advancements in medical By applying Starpharma's DEP® diagnosis and treatment, many Drug/Payload (e.g., technology in dev
Slide 29: Starpharma's Revitalised R&D Program
Starpharma's Revitalised R&D Program to Support Accelerated Pipeline & Go-No-Go Decisions Process & Governance •Innovation, stage-gate process, and project management People & Skill Tools & Data •Expand resources and •Efficiency in using global capability to match data access, analytics, targeted op
Slide 30: Creating Novel and Competitive Assets
Creating Novel and Competitive Assets with Our Target Product Profile for the DEP® Radiopharmaceutical Assets Product Characteristics • Real-time, accurate assessment of HER2+ tumour status (including low HER2+) • Precise, total-body imaging of HER2+ tumours without the need for a biopsy • Accuratel
Slide 31: DEP Radiopharmaceuticals Pathway to the Clinic
DEP® Radiopharmaceuticals Pathway to the Clinic Targeting a First-in-Patient Clinical Trial in 2025 Estimated Timeline Phase 1 commences Phase 1 Diagnostic results Preclinical Work Phase 2 commences Complete 2H 1H 2H 1H CY2025 CY2026 CY2026 CY2027 Preclinical work Phase 1 results Phase 1 complete co
Slide 32: Accelerate Early Asset Development
Phase II Clinical Assets Rapidly Strategic Accelerate Early Emerging Partnerships Therapies DEP Asset Development Platform Novel Areas OTC of Unmet Products on Need Market Annual General Meeting 2024 29
Slide 33: Extensive Partnership Experience, Multiple Opportunities
Extensive Partnership Experience, Multiple Opportunities for Value Creation Benefits of DEP® partnerships • Leverage existing and create new intellectual property Medicxi Collaboration (Petalion Therapeutics) • Broaden the applications of Genentech Partnership DEP®, creating multiple potential reven
Slide 34: Extensive Partnership Experience, Broad DEP Application Opportunity
Extensive Partnership Experience, Broad DEP® Application Opportunity and a Flexible Approach to Collaboration Current Partnerships Types of Partnerships Progress with Expanding and Collaborations Partnerships •R&D collaborations •Multiple meetings and •Co-development CDAs with prospective •License p
Slide 35: Developing an Innovative Cancer Therapy with Medicxi
Developing an Innovative Cancer Therapy in Collaboration with Medicxi, a Leading Healthcare Investment Firm Asset- SPL receives 22.5% equity in Petalion in centric exchange for licensing specific IP approach Novel asset SPL maintains background IP development Revenue stream Highly from fee-for-servi
Slide 36: Build Long-term Sustainability
Phase II Clinical Assets Rapidly Strategic Build Long-term Emerging Partnerships Therapies DEP Sustainability Platform Novel Areas OTC of Unmet Products on Need Market Annual General Meeting 2024 33
Slide 37: Maximise Revenue for VivaGel BV and Viraleze Nasal Spray
Maximise Revenue for VivaGel® BV and Viraleze Nasal Spray Secure New Partners and Enhance Marketing VivaGel® BV – a non-antibiotic topical Viraleze - a topical antiviral barrier gel for the treatment of bacterial nasal spray for colds and respiratory vaginosis (BV) and prevention of viruses, includi
Slide 38: Revitalised VIRALEZE Digital Presence
Revitalised VIRALEZE Digital Presence Targeted Advertising in the UK and Germany Ongoing Digital Marketing Revamped E-commerce Store to FY25 Sales to Date: Campaigns Launch in CY2025 Up 20% • Enhanced focus on key target Top 2 Countries by Sales: audiences UK and Germany • Conversion-focused design
Slide 39: Well Positioned to Accelerate Product Pipeline
Well Positioned to Accelerate Product Pipeline and Strategic Growth Initiatives FY24 Result Multiple Revenue Streams • Revenue $9.8M* (FY24 $4.2M) • Licenses and Milestone Payments • Loss $8.2M* (FY24 $15.6M) • Marketed Products: VivaGel® BV • Decrease in expenses related to: and Viraleze • Completi
Slide 40: Catalysts to Anticipate in The Next 12 Months
Catalysts to Anticipate in The Next 12 Months Poised for Value Creation 1) License / collaboration for a DEP® asset to commercialise Over 20 years of experience in advancing dendrimer 2) Radiodiagnostic progress to the clinic technology from the lab to the patient. 3) Strategic partnerships – expans
Slide 41: Confidence to Deliver the Plan is Based on
Confidence to Deliver the Plan is Based on: • Dendrimer experience & benefit • Focused strategy: execution process & governance is key • Improved internal alignment & ways of working • Leverage the learnings of the past • Strength in SPL’s unique value proposition • Capability: chemistry, research &
Slide 42: Starpharma Leadership Team
Starpharma Leadership Team Cheryl Maley, BSc, DipEd, MBA, GAICD, Justin Cahill, BBus, MPA, CPA Chief Executive Officer and Managing Director Chief Financial Officer and Company Secretary 25+ years in the pharmaceutical industry, including at 15+ years of experience in corporate finance and leadershi
Slide 43: Thank you.
ASX : SPL US OTC : SPHRY Thank you. Investor Relations Corporate Office Investor.Relations@Starpharma.com 4 – 6 Southampton Crescent www.starpharma.com Abbotsford, Victoria 3067 Australia
Starpharma Holdings — Shareholder Meeting (November 2024) on 6ix